Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Invitae Reports $53.5 Million in Quarterly Revenue Driven by More Than 111,000 Samples in Quarterly Volume

      -- Increased quarterly revenue by 43% and volume by 52% year-over-year --

      -- Announced appointment of Sean George as chairman of the Board of Directors, retirement of Randy Scott as executive chairman, effective September 1, 2019 --

      -- Hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific --

      Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people.  www.invitae.com (PRNewsFoto/Invitae Corporation)

      News provided by

      Invitae Corporation

      Aug 06, 2019, 16:15 ET

      Share this article

      Share this article


      SAN FRANCISCO, Aug. 6, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the second quarter ended June 30, 2019.

      "We have now delivered our 25th quarter of impressive growth in both revenue and volume, while continuing to invest in new technologies that further our position as a leader in the rapidly evolving genetics industry," said Sean George, co-founder and chief executive officer of Invitae. "We are beginning to stand out to our customers as the company that offers the most comprehensive menu of high-quality, affordable genetic testing to everyone who can benefit, enabling us to bring genetics more broadly into mainstream medicine. With the success we've had in the first half of the year, we are confident in our ability to achieve our 2019 guidance."

      Second Quarter 2019 Financial Results

      • Accessioned more than 111,000 samples in the second quarter of 2019, representing a 52% increase over the more than 73,000 samples in the second quarter of 2018. Billable volume was nearly 111,000 in the second quarter of 2019
      • Generated revenue of $53.5 million in the second quarter of 2019, representing a 43% increase over the second quarter of 2018 revenue of $37.3 million
      • Reported the average cost per sample at $252 in the second quarter of 2019, representing a 10% reduction from a $279 average cost per sample in the second quarter of 2018
      • Achieved gross profit of $25.5 million in the second quarter of 2019 compared to $16.9 million in gross profit in the second quarter of 2018

      Total operating expenses, which exclude cost of revenue, for the second quarter of 2019 were $77.4 million, which includes $25.3 million in research and development, $21.3 million in general and administrative and $30.8 million in sales and marketing expenses for the quarter.  Comparatively, total operating expenses for the second quarter of 2018 was $46.9 million. Contributing to the increase in operating expense was acquisition-related costs.

      For the second quarter of 2019, Invitae reported a net loss of $48.7 million, or a $0.54 loss per share, compared to a net loss of $31.7 million in the second quarter of 2018, or a $0.47 net loss per share. Excluding acquisition-related expenses and income tax benefit, our non-GAAP net loss was $46.8 million in the second quarter of 2019, or a $0.52 non-GAAP net loss per share.

      As of June 30, 2019, cash, cash equivalents, restricted cash, and marketable securities totaled $254.0 million. Net decrease in cash, cash equivalents and restricted cash for the quarter was $5.1 million.  Cash burn for the quarter was $33.2 million.  

      Invitae's Corporate and Scientific Highlights

      • Reduced patient-pay pricing for its non-invasive prenatal screening (NIPS) to $99, increasing access to testing for women in early pregnancy
      • Announced the addition of supplemental RNA testing for variants of uncertain significance (VUS), beginning with patients undergoing cancer testing, to contribute to research and further reduce the uncertainty inherent in genetic testing results
      • Launched Invitae's direct channel to make it easier for customers to order and receive the same high-quality, medical genetic testing from Invitae that experts use and trust
      • Continued progress with payers, as Invitae was named one of seven labs in UnitedHealthcare's (UHC) Preferred Lab Network (PLN), effective as of July 1, 2019j. The PLN was designed to make it easier for providers to choose from UHC's broader network of more than 300 labs, based on a rigorous quality review process. Services accessed through the PLN are at a lower average cost than other lab providers
      • Presented various studies at The American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting generated by researchers from Invitae
        • Shared data on the limitations of a direct-to-consumer strategy testing that detects only three of the thousands of genetic variants in BRCA1 and BRCA2 associated with hereditary breast and ovarian cancer (HBOC) risk, showing this strategy results in a clinical false negative rate of approximately 90% of those at risk for HBOC
        • Shared data from more than 113,000 patients that support broadening genetic testing guidelines to include patients with potentially actionable germline variants that are missed when clinicians adhere to current guidelines
      • Presented research at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating the importance of germline multigene panel testing in guiding therapy for expanding groups of cancer patients can impact patient outcomes and inform surgical strategy, treatments, and clinical trial eligibility
      • Continued investment in M&A to drive technologies to scale the business and improve quality
        • Acquired Singular Bio, Inc., a privately held company developing single molecule detection technology enabling lower costs and expanded use of high-quality cell-free, nucleic acid analysis, initially for application in NIPS
        • Acquired Jungla Inc., a privately held company funded by Andreessen Horowitz (a16z) that has developed a cloud-based platform that further enhances Invitae's genetic variant interpretation and ability to deliver high-quality, more affordable genetic testing
      • Extended Invitae's genome network with the addition of 12 new biopharma partnership programs in the second quarter of 2019
        • Launched ID YOUR IRD, an initiative with Spark Therapeutics, to offer genetic testing at no charge to patients suspected by their healthcare providers of having an inherited retinal disease (IRD), a group of rare, progressive eye disorders that may result in vision loss or blindness caused by inherited genetic changes
        • Announced the availability of its Detect programs to provide no-charge genetic testing to improve diagnosis and treatment in four conditions: muscular dystrophy, hereditary prostate cancer, cardiomyopathy and arrhythmia and lysosomal storage diseases
      • Announced the appointment of Sean George as the new chairman of the board of directors and the retirement of executive chairman Randy Scott, effective September 1, 2019

      "During my 35 years in the biotech industry, it has been amazing to watch the genomics field emerge from the early days of the human genome project to now affecting millions of lives around the world," said Randy Scott, executive chairman. "I couldn't be more proud to be a part of the Invitae story, and I look forward to following the progress of a great team on a great mission to make genetic information more affordable and accessible for all. I plan to continue to support the Invitae team as a private investor and look forward to the tremendous growth that lies ahead."

      "Given the stage of growth we're in, we are confident in our ability to scale as we bring genetics to mainstream medicine, and Randy's leadership and vision have been central to getting us here," said Sean George. "We're deeply grateful to Randy for his passion for Invitae's success and for his role as a pioneer and innovator in the genetics industry."

      Webcast and Conference Call Details
      Management will host a conference call and webcast today at 4:30 p.m. Eastern / 1:30 p.m.  Pacific to discuss financial results and recent developments. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 6153749. Following prepared remarks, management will respond to questions from investors and analysts, subject to time limitations.

      The live webcast of the call and slide deck may be accessed by visiting the investors section of the company's website at ir.invitae.com.  A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website.

      About Invitae
      Invitae Corporation (NYSE: NVTA) is the leading advanced medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com.

      Safe Harbor Statement
      This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's financial results for the quarter ended June 30, 2019; estimated guidance for 2019 and future financial performance; the impact of the company's acquisitions, product offerings and distribution channels; the retirement plans of the company's executive chairman, appointment of a new chairman, and the timing thereof; and the company's beliefs regarding the growth of its business, its position and impact on the genetic testing industry, its success in executing on its mission and achieving its goals, and the benefits of genetic testing. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the actual results for the quarter ended June 30, 2019 and the year ending December 31, 2019; the company's ability to continue to grow its business; the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the company's failure to successfully integrate or fully realize the anticipated benefits of acquired businesses; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

      Non-GAAP Financial Measures
      To supplement Invitae's consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP), the company is providing non-GAAP research and development expense, non-GAAP general and administrative expense, non-GAAP net loss and net loss per share, and cash burn, which are non-GAAP financial measures. These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly-titled measures presented by other companies. Management believes these non-GAAP financial measures are useful to investors in evaluation the company's ongoing operating results and trends.

      Non-GAAP research and development expense, non-GAAP general and administrative expense and non-GAAP net loss exclude acquisition-related stock-based compensation related to inducement grants, post-combination expense related to the acceleration of equity grants in connection with the company's business combinations, and acquisition-related income tax benefits. These non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on the reported financial results. Management accounts for this limitation by analyzing results on a GAAP basis as well as a non-GAAP basis and also by providing GAAP measures in the company's public disclosures.

      Cash burn excludes (1) changes in marketable securities other than investments made in privately held companies, (2) cash received from equity financings, including proceeds from a public offering of common stock in March 2019, (3) cash received from loan proceeds, and (4) cash received from exercises of warrants. Management believes cash burn is a liquidity measure that provides useful information to management and investors about the amount of cash consumed by the operations of the business. A limitation of using this non-GAAP measure is that cash burn does not represent the total change in cash, cash equivalents, and restricted cash for the period because it excludes cash provided by or used for other operating, investing or financing activities. Management accounts for this limitation by providing information about the company's operating, investing and financing activities in the statements of cash flows in the consolidated financial statements in the company's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and by presenting net cash provided by (used in) operating, investing and financing activities as well as the net increase in cash, cash equivalents and restricted cash in reconciliation of cash burn.

      In addition, other companies, including companies in the same industry, may not use cash burn, non-GAAP research and development and general and administrative expense, or non-GAAP net loss or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-GAAP measures as comparative measures. Because of these limitations, the company's non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the non-GAAP reconciliations provided in the table below.

      INVITAE CORPORATION


      Consolidated Balance Sheets
      (in thousands)
      (unaudited)



      June 30,

      2019


      December 31,

      2018

      Assets




      Current assets:




      Cash and cash equivalents

      $

      247,000



      $

      112,158


      Marketable securities

      800



      13,727


      Accounts receivable

      23,143



      26,296


      Prepaid expenses and other current assets

      16,976



      13,258


      Total current assets

      287,919



      165,439


      Property and equipment, net

      29,021



      27,886


      Operating lease assets

      40,228



      —


      Restricted cash

      6,243



      6,006


      Intangible assets, net

      57,832



      30,469


      Goodwill

      76,556



      50,095


      Other assets

      5,103



      3,064


      Total assets

      $

      502,902



      $

      282,959


      Liabilities and stockholders' equity




      Current liabilities:




      Accounts payable

      $

      5,255



      $

      7,812


      Accrued liabilities

      27,801



      26,563


      Operating lease obligations

      5,102



      —


      Finance lease obligations

      1,934



      1,937


      Total current liabilities

      40,092



      36,312


      Operating lease obligations, net of current portion

      45,694



      —


      Finance lease obligations, net of current portion

      429



      1,375


      Debt

      75,184



      74,477


      Other long-term liabilities

      —



      8,956


      Total liabilities

      161,399



      121,120


      Stockholders' equity:




      Common stock

      9



      8


      Accumulated other comprehensive income (loss)

      —



      (5)


      Additional paid-in capital

      944,559



      678,548


      Accumulated deficit

      (603,065)



      (516,712)


      Total stockholders' equity

      341,503



      161,839


      Total liabilities and stockholders' equity

      $

      502,902



      $

      282,959


      INVITAE CORPORATION






      Consolidated Statements of Operations
      (in thousands, except per share data)
      (unaudited)








      Three Months Ended

      June 30,


      Six Months Ended

      June 30,



      2019


      2018


      2019


      2018

      Revenue:









      Test revenue


      $

      52,302



      $

      36,350



      $

      91,921



      $

      63,403


      Other revenue


      1,173



      956



      2,107



      1,574


      Total revenue


      53,475



      37,306



      94,028



      64,977


      Cost of revenue


      28,006



      20,447



      49,260



      38,523


      Research and development


      25,302



      15,784



      43,296



      31,150


      Selling and marketing


      30,779



      18,707



      54,972



      37,631


      General and administrative


      21,274



      12,436



      34,593



      24,216


      Loss from operations


      (51,886)



      (30,068)



      (88,093)



      (66,543)


      Other income, net


      1,381



      188



      2,019



      1,835


      Interest expense


      (2,121)



      (1,791)



      (4,229)



      (3,083)


      Net loss before taxes


      (52,626)



      (31,671)



      (90,303)



      (67,791)


      Income tax benefit


      (3,950)



      —



      (3,950)



      —


      Net loss


      $

      (48,676)



      $

      (31,671)



      $

      (86,353)



      $

      (67,791)


      Net loss per share, basic and diluted


      $

      (0.54)



      $

      (0.47)



      $

      (1.01)



      $

      (1.12)


      Shares used in computing net loss per share, basic and diluted


      90,863



      67,807



      85,148



      60,775


      INVITAE CORPORATION


      Consolidated Statements of Cash Flows
      (in thousands)
      (unaudited)



      Six Months Ended June 30,


      2019


      2018

      Cash flows from operating activities:




      Net loss

      $

      (86,353)



      $

      (67,791)


      Adjustments to reconcile net loss to net cash used in operating activities:




      Depreciation and amortization

      6,725



      6,927


      Stock-based compensation

      19,540



      10,505


      Remeasurements of liabilities associated with business combinations

      (286)



      709


      Benefit from income taxes

      (3,950)



      —


      Other

      1,182



      462


      Changes in operating assets and liabilities, net of business acquired:




      Accounts receivable

      3,153



      (4,037)


      Prepaid expenses and other current assets

      (3,825)



      (512)


      Other assets

      2,410



      (1,428)


      Accounts payable

      (3,954)



      (3,106)


      Accrued expenses and other liabilities

      4,267



      (396)


      Net cash used in operating activities

      (61,091)



      (58,667)






      Cash flows from investing activities:




      Purchases of marketable securities

      (20,781)



      (900)


      Proceeds from sales of marketable securities

      —



      19,965


      Proceeds from maturities of marketable securities

      34,000



      2,078


      Acquisition of business, net of cash acquired

      3,193



      —


      Purchases of property and equipment

      (8,824)



      (3,084)


      Net cash provided by investing activities

      7,588



      18,059






      Cash flows from financing activities:




      Proceeds from public offerings of common stock, net of issuance costs

      184,490



      53,480


      Proceeds from issuance of common stock

      5,123



      4,933


      Proceeds from debt financing

      —



      19,781


      Finance lease principal payments

      (1,031)



      (1,170)


      Net cash provided by financing activities

      188,582



      77,024






      Net increase in cash, cash equivalents and restricted cash

      135,079



      36,416


      Cash, cash equivalents and restricted cash at beginning of period

      118,164



      17,459


      Cash, cash equivalents and restricted cash at end of period

      $

      253,243



      $

      53,875


      INVITAE CORPORATION


      Reconciliation of GAAP to Non-GAAP Research and Development Expense
      (in thousands)
      (unaudited)




      Three Months Ended

      June 30,


      Six Months Ended

      June 30,



      2019


      2018


      2019


      2018

      Research and development


      $

      25,302



      $

      15,784



      $

      43,296



      $

      31,150


      Acquisition-related stock-based compensation


      (2,586)



      —



      (2,586)



      —


      Non-GAAP research and development


      $

      22,716



      $

      15,784



      $

      40,710



      $

      31,150


      Reconciliation of GAAP to Non-GAAP General and Administrative Expense
      (in thousands)
      (unaudited)




      Three Months Ended

      June 30,


      Six Months Ended

      June 30,



      2019


      2018


      2019


      2018

      General and administrative


      $

      21,274



      $

      12,436



      $

      34,593



      $

      24,216


      Acquisition-related post-combination expense


      (3,212)



      —



      (3,212)



      —


      Non-GAAP general and administrative


      $

      18,062



      $

      12,436



      $

      31,381



      $

      24,216


      Reconciliation of Net Loss to Non-GAAP Net Loss Per Share
      (in thousands, except per share data)
      (unaudited)




      Three Months Ended

      June 30,


      Six Months Ended

      June 30,



      2019


      2018


      2019


      2018

      Net loss


      $

      (48,676)



      $

      (31,671)



      $

      (86,353)



      $

      (67,791)


      Acquisition-related stock-based compensation


      2,586



      —



      2,586



      —


      Acquisition-related post-combination expense


      3,212



      —



      3,212



      —


      Acquisition-related income tax benefit


      (3,950)



      —



      (3,950)



      —


      Non-GAAP net loss


      $

      (46,828)



      $

      (31,671)



      $

      (84,505)



      $

      (67,791)











      Non-GAAP net loss per share, basic and diluted


      $

      (0.52)



      $

      (0.47)



      $

      (0.99)



      $

      (1.12)


      Shares used in computing net loss per share, basic and diluted


      90,863



      67,807



      85,148



      60,775


      INVITAE CORPORATION


      Reconciliation of Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash to Cash Burn
      (in thousands)
      (unaudited)



      Three Months
      Ended March 31, 2019


      Three Months
      Ended June 30, 2019


      Six Months
      Ended June 30, 2019




      Net cash used in operating activities

      (28,366)



      (32,725)



      (61,091)


      Net cash provided by (used in) investing activities

      (17,545)



      25,133



      7,588


      Net cash provided by (used in) financing activities

      186,120



      2,462



      188,582


      Net increase (decrease) in cash, cash equivalents and restricted cash

      140,209



      (5,130)



      135,079








      Adjustments:






      Purchases of investments

      20,781



      —



      20,781


      Maturities of investments

      (6,000)



      (28,000)



      (34,000)


      Proceeds from public offering of common stock, net of issuance costs

      (184,490)



      —



      (184,490)


      Proceeds from exercises of warrants

      (88)



      (25)



      (113)


      Cash burn

      (29,588)



      (33,155)



      (62,743)


      Contact:
      Laura D'Angelo
      [email protected]
      (628) 213-3369

      SOURCE Invitae Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.